EBErkin Bilalov

Erkin Bilalov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Erkin Bilalov has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prognostic value of postoperative circulating tumor DNA for recurrence-free survival in resected non-small cell lung cancer: a systematic review and meta-analysis

    by Atta Ullah Khan, Intizor Avazmetova, Mukhayya Ruzieva, Barno Matchanova, Asilbek Dauletbaev, Erkin Bilalov, Muhammad Ibrahim

    Background Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for minimal residual disease (MRD) detection in resected non-small cell lung cancer (NSCLC), offering potential for risk stratification and treatment optimization in the postoperative setting. Objective To conduct a systematic review and meta-analysis evaluating the prognostic value of postoperative ctDNA detection for recurrence-free survival and overall survival in patients with surgically resected NSCLC. Methods We systematically searched multiple databases including PubMed, Embase, Web of Science, Scopus, and Cochrane Library, identifying 1,640 initial records. After screening and eligibility assessment, 13 studies encompassing 1,309 patients were included in the quantitative synthesis. Results Immediate postoperative ctDNA detection (4 studies, n = 556) demonstrated a hazard ratio of 6.41 (95% CI: 4.18–9.83, P < 0.00001, I2 = 0%) for recurrence-free survival. MRD assessment (9 studies, n = 1,107) yielded HR = 5.48 (95% CI: 3.71–8.10, P < 0.00001, I2 = 38%). Longitudinal ctDNA monitoring (8 studies, n = 1,102) showed the strongest association with HR = 8.70 (95% CI: 6.03–12.54, P < 0.00001, I2 = 21%). Post-adjuvant chemotherapy ctDNA positivity (3 studies, n = 460) resulted in HR = 2.85 (95% CI: 1.56–5.21, P = 0.0006, I2 = 0%). Overall survival analysis (5 studies) demonstrated HR = 4.47 (95% CI: 2.66–7.52, P < 0.00001, I2 = 0%). Conclusions Postoperative ctDNA detection independently predicts prognosis in resected NSCLC, consistently indicating recurrence risk and guiding adjuvant therapy decisions.